Published in Exp Hematol on January 01, 2002
Selective purging of human multiple myeloma cells from autologous stem cell transplantation grafts using oncolytic myxoma virus. Biol Blood Marrow Transplant (2012) 1.06
Reovirus as a successful ex vivo purging modality for multiple myeloma. Bone Marrow Transplant (2013) 0.81
Molecular purging of multiple myeloma cells by ex-vivo culture and retroviral transduction of mobilized-blood CD34+ cells. J Transl Med (2007) 0.79
The ex vivo purge of cancer cells using oncolytic viruses: recent advances and clinical implications. Oncolytic Virother (2015) 0.75
High-dose therapy improves progression-free survival and survival in relapsed follicular non-Hodgkin's lymphoma: results from the randomized European CUP trial. J Clin Oncol (2003) 2.65
FGFR3 dysregulation in multiple myeloma: frequency and prognostic relevance. Br J Haematol (2002) 2.07
European Myeloma Network recommendations on the evaluation and treatment of newly diagnosed patients with multiple myeloma. Haematologica (2014) 1.57
Intramyocardial injection of vascular endothelial growth factor-A165 plasmid followed by granulocyte-colony stimulating factor to induce angiogenesis in patients with severe chronic ischaemic heart disease. Eur Heart J (2006) 1.10
Vaccination with p53 peptide-pulsed dendritic cells is associated with disease stabilization in patients with p53 expressing advanced breast cancer; monitoring of serum YKL-40 and IL-6 as response biomarkers. Cancer Immunol Immunother (2007) 1.05
Vaccination with p53-peptide-pulsed dendritic cells, of patients with advanced breast cancer: report from a phase I study. Cancer Immunol Immunother (2004) 1.02
The in vivo toxicity of hydroxyurea depends on its direct target catalase. J Biol Chem (2010) 0.99
In multiple myeloma clonotypic CD38- /CD19+ / CD27+ memory B cells recirculate through bone marrow, peripheral blood and lymph nodes. Leuk Lymphoma (2004) 0.97
Early changes in serum IL-6 and VEGF levels predict clinical outcome following first-line therapy in aggressive non-Hodgkin's lymphoma. Ann Hematol (2005) 0.97
Positron emission tomography/computed tomography surveillance in patients with Hodgkin lymphoma in first remission has a low positive predictive value and high costs. Haematologica (2011) 0.96
Loss of MicroRNA targets in the 3' untranslated region as a mechanism of retroviral insertional activation of growth factor independence 1. J Virol (2009) 0.92
Idiotype vaccination in multiple myeloma induced a reduction of circulating clonal tumor B cells. Blood (2003) 0.90
Multiplex reverse transcription polymerase chain reaction screening in acute myeloid leukemia detects cytogenetically unrevealed abnormalities of prognostic significance. Haematologica (2005) 0.88
MyelomA Genetics International Consortium. Leuk Lymphoma (2012) 0.86
Anemia and erythropoiesis-stimulating agent administration in patients with non-Hodgkin lymphoma treated with cyclophosphamide, doxorubicin, vincristine, and prednisolone ± rituximab chemotherapy: results from an observational study. Leuk Lymphoma (2011) 0.84
Identification of ID-1 as a potential target gene of MMSET in multiple myeloma. Br J Haematol (2005) 0.82
Exposure time independent summary statistics for assessment of drug dependent cell line growth inhibition. BMC Bioinformatics (2014) 0.81
Reproducible probe-level analysis of the Affymetrix Exon 1.0 ST array with R/Bioconductor. Brief Bioinform (2014) 0.80
C-MAF oncogene dysregulation in multiple myeloma: frequency and biological relevance. Leuk Lymphoma (2003) 0.80
Stable phenotype of B-cell subsets following cryopreservation and thawing of normal human lymphocytes stored in a tissue biobank. Cytometry B Clin Cytom (2014) 0.78
Impact of 18F-fluorodeoxyglucose positron emission tomography/computed tomography staging in newly diagnosed classical Hodgkin lymphoma: fewer cases with stage I disease and more with skeletal involvement. Leuk Lymphoma (2014) 0.77
Clinical impact of leukemic blast heterogeneity at diagnosis in cytogenetic intermediate-risk acute myeloid leukemia. Cytometry B Clin Cytom (2012) 0.77
Urine microscopy--an important diagnostic tool. Tidsskr Nor Laegeforen (2014) 0.77
The CD19 compartment in myeloma includes a population of clonal cells persistent after high-dose treatment. Leuk Lymphoma (2002) 0.76
Gene expression profiling of murine T-cell lymphoblastic lymphoma identifies deregulation of S-phase initiating genes. Leuk Res (2013) 0.76
FGFR3 dysregulation and clinical outcome in myeloma. Br J Haematol (2003) 0.75
A model system for assessing and comparing the ability of exon microarray and tag sequencing to detect genes specific for malignant B-cells. BMC Genomics (2012) 0.75
[Acute lymphoblastic leukaemia in Danish children and young people 10 to 19 years of age. Should young adults with acute lymphoblastic leukaemia be treated in the same way as children?]. Ugeskr Laeger (2006) 0.75
Alternative pre-mRNA splicing leads to potential biomarkers in diffuse large B-cell lymphoma - a systematic review. Dan Med J (2016) 0.75
[Mobilisation of haematopoietic stem cells with plerixafor--secondary publication]. Ugeskr Laeger (2009) 0.75
[Mesenchymal stem cell therapy--the key to regenerative medicine?]. Ugeskr Laeger (2003) 0.75
[Complete remission after Rituximab treatment in refractory hairy cell leukemia]. Ugeskr Laeger (2008) 0.75
[Stem cell harvesting after plerixafor treatment]. Ugeskr Laeger (2009) 0.75
Prediction of haemorrhage in the early stage of acute myeloid leukaemia by flow cytometric analysis of platelet function. Br J Haematol (2005) 0.75